- Home
- VTAK vs BDRX Comparison
VTAK vs BDRX Comparison
Compare VTAK & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTAK | BDRX |
|---|---|---|
| Founded | 2002 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.6M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VTAK | BDRX |
|---|---|---|
| Price | $0.20 | $1.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 41.0K |
| Earning Date | 08-11-2026 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $442,000.00 | N/A |
| Revenue This Year | $1,170.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3057.14 | N/A |
| 52 Week Low | $0.20 | $0.60 |
| 52 Week High | $3.20 | $11.88 |
Technical Indicators
Market Signals| Indicator | VTAK | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.13 | 31.78 |
| Support Level | N/A | $1.03 |
| Resistance Level | $0.31 | $1.60 |
| Average True Range (ATR) | 0.03 | 0.19 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 16.12 | 23.26 |
Price Performance
Historical ComparisonAbout VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.